TY - JOUR AU - Poposka, Lidija AU - Boskov, Vladimir AU - Risteski, Dejan AU - Taleski, Jane AU - Georgievska-Ismail, Ljubica PY - 2016/04/20 Y2 - 2024/03/28 TI - Anticoagulation Management in Patients with Pacemaker-Detected Atrial Fibrillation JF - Open Access Macedonian Journal of Medical Sciences JA - Open Access Maced J Med Sci VL - 4 IS - 2 SE - B - Clinical Sciences DO - 10.3889/oamjms.2016.053 UR - https://oamjms.eu/index.php/mjms/article/view/oamjms.2016.053 SP - 243-247 AB - <p><strong>INTRODUCTION: </strong>In patients with an implanted pacemaker, asymptomatic atrial fibrillation (AF) is associated with an increased risk of thrombo-embolic complications. There is still no consensus which duration of episodes of atrial fibrillation should be taken as an indicator for inclusion of oral anticoagulation therapy (OAC). <strong></strong></p><p><strong>MATERIAL AND METHODS: </strong>A total of 104 patients who had no AF episodes in the past and have an indication for permanent pacing were included in the study.</p><p><strong>RESULTS: </strong>During an average follow-up of 18 months, 33 of the patients developed episodes of AF. Inclusion of OAC was performed in 17 patients, in whom AF was recorded, although in all patients CHA2DS2-VASc score was ≥ 1. The inclusion of OAC showed a statistically significant correlation with increasing duration of episodes of AF (r = 0.502, p = 0.003). During the follow-up period none of the patients developed thrombo-embolic complication. <strong></strong></p><strong>CONCLUSION: </strong>Considering that our group of patients had no thrombo-embolic events, we could conclude that dividing the AF episodes in less than 1% in 24 hours and longer than 1% within 24 hours could be an indicator for decision-making to include OAK if the CHA2DS2-VASc score is ≥ 1. ER -